Thermal wounds are complex and lethal with irregular shapes, risk of infection, slow healing, and large surface area. The mortality rate in patients with infected burns is twice that of non-infected burns. Developing multifunctional skin substitutes to augment the healing rate of infected burns is vital. Herein, we 3D printed a hydrogel scaffold comprising carboxymethyl chitosan (CMCs) and oxidized alginate grafted catechol (O-AlgCat) on a hydrophobic electrospun layer, forming a bilayer skin substitute (BSS). The functional layer (FL) was fabricated by physiochemical crosslinking to ensure favorable biodegradability. The gallium-containing hydrophobic electrospun layer or backing layer (BL) could mimic the epidermis of skin, avoiding fluid penetration and offering antibacterial activity. 3D printed FL contains catechol, gallium, and biologically active platelet rich fibrin (PRF) to adhere to both tissue and BL, show antibacterial activity, encourage angiogenesis, cell growth, and migration. The fabricated bioactive BSS exhibited noticeable adhesive properties (P ≤ 0.05), significant antibacterial activity (P ≤ 0.05), faster clot formation, and the potential to promote proliferation (P ≤ 0.05) and migration (P ≤ 0.05) of L929 cells. Furthermore, the angiogenesis was significantly higher (P ≤ 0.05) when evaluated in vivo and in ovo. The BSS-covered wounds healed faster due to low inflammation and high collagen density. Based on the obtained results, the fabricated bioactive BSS could be an effective treatment for infected burn wounds.

Glioblastoma multiforme (GBM) has several distinctive characteristics linked to a poor early-stage prognosis. The crucial obstacle in the treatment of GBM is the inability of chemo drugs or other anticancer medicines to reach brain tumors due to the blood–brain tumor barrier (BBTB), leading to weak cytotoxic activity and drug resistance. Additionally, there is a limited number of clinically approved anticancer medicines for GBM because of the heterogeneity of this type of tumor. Presently, four FDA-approved drugs are available for the treatment of GBM, i.e., temozolomide, lomustine, carmustine, and bevacizumab. These drugs are primarily used to treat recurrent high-grade gliomas and their symptoms. Unfortunately, despite efforts to treat GBM over the last 60 years, no significant progress has been made in extending the overall survival (OS) of patients with this disease. Therefore, possible treatments and accessible drugs must be modified or advanced medicines developed to treat GBM. Several innovative strategies have been used to overcome these challenges, such as combining traditional therapies with emerging nanoscale-based biomaterials for multifunctional characteristics. These modified nanoscale biomaterials can cross the blood–brain barrier (BBB) and increase chemo-drug sensitivity through improved accumulation and efficiency. Herein, we review the recent developments in organic and inorganic biomaterial-based nanoparticles for GBM drug delivery. Firstly, we present a brief overview of the FDA-approved drugs and some additional chemo drugs for treating GBM, followed by a discussion on the drawbacks of the delivery of these drugs in GBM. Further, the current challenges in the field of GBM drug delivery, significant advancements in biomaterials research to overcome these obstacles, and subsequent considerations and opportunities for the application of biomaterials in the clinical treatment of GBM are highlighted.